A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Phase 3 Completed 132 enrolled Sumitomo Pharma America, Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

A study to evaluate the efficacy and safety of dasotraline in children 6 years of age to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.

Timeline

Start: 2016-04-30
Primary completion: 2017-02-28
Completion: 2017-02-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dasotraline	Small molecule	4 mg	—

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

Summary

Timeline

Drugs

Indications